[Systemic effect of diflucortolone valerate after dermal application (author's transl)].
The systemic effect of 6alpha,9-difluor-11beta-hydroxy-16alpha-methyl-21-valeryloxy-1,4-pregnadiene-3,20-dione (diflucortolone valerate, Nerisona) 0.1% as an ointment and fatty ointment was investigated in two studies. The parameters used were the plasma 11-OHCS values and the urinary 17-OHCS and 17-KS values, respectively. Suppression of the plasma cortisol values was observed after topical application of both diflucortolone valerate and betamethasone-17-valerate to healthy subjects under extreme conditions of whole-body occlusion. However, it was still possible to stimulate the adrenal cortex with ACTH. No reduction of the 17-OHCS of 17-KS values in the 24-h urine was observed during open, large-surface treatment of patients with skin diseases.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000287:Administration, Topical; D000311:Adrenal Glands / Q000187:drug effects*; D000324:Adrenocorticotropic Hormone; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001624:Betamethasone Valerate / Q000494:pharmacology; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D009823:Ointment Bases; D011244:Pregnadienediols / Q000494:pharmacology*; D012871:Skin Diseases / Q000188:drug therapy; D013259:Steroids, Fluorinated / Q000494:pharmacology
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D000893:Anti-Inflammatory Agents; D009823:Ointment Bases; D011244:Pregnadienediols; D013259:Steroids, Fluorinated; D000324:Adrenocorticotropic Hormone; D001624:Betamethasone Valerate; D006854:Hydrocortisone
Systemische Wirkung von Diflucortolonvalerianat nach dermaler Applikation